https://www.selleckchem.com/pr....oducts/ono-ae3-208.h
05), while the efficacy for mediate patients and frail patients showed no significant difference. During the induction of bortezomib, the incidence of adverse reactions for the patients in the triple group (78.6%) was higher than 67.9% in the double group, and the difference showed no statistically significant (P0.05).There was no significant difference in the 1-year overall survival rate of the patients and with molecular genetic abnormalities among each groups. The therapeutic effect is related to the patient's physical condit
Me gusta
Comentario
Compartir
